In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of GlycoMimetics Inc (NASDAQ: GLYC) closed at $1.92 in the last session, down -10.88% from day before closing price of $2.16. In other words, the price has decreased by -$10.88 from its previous closing price. On the day, 1.17 million shares were traded. GLYC stock price reached its highest trading level at $2.17 during the session, while it also had its lowest trading level at $1.88.
Ratios:
We take a closer look at GLYC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.41 and its Current Ratio is at 6.41. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on December 22, 2023, initiated with a Overweight rating and assigned the stock a target price of $12.
On November 12, 2021, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $3 to $4.
On November 14, 2019, ROTH Capital started tracking the stock assigning a Buy rating and target price of $12.ROTH Capital initiated its Buy rating on November 14, 2019, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 22 ’23 when Rock Edwin bought 30,403 shares for $1.38 per share. The transaction valued at 41,956 led to the insider holds 375,403 shares of the business.
Rock Edwin bought 35,000 shares of GLYC for $48,300 on Sep 21 ’23. The Chief Medical Officer now owns 345,000 shares after completing the transaction at $1.38 per share. On May 17 ’23, another insider, Hahn Brian M., who serves as the SVP Finance, CFO of the company, sold 3,700 shares for $1.95 each. As a result, the insider received 7,215 and left with 53,143 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLYC now has a Market Capitalization of 124067016 and an Enterprise Value of 83082560. For the stock, the TTM Price-to-Sale (P/S) ratio is 12406.62 while its Price-to-Book (P/B) ratio in mrq is 3.23. Its current Enterprise Value per Revenue stands at 8308.256 whereas that against EBITDA is -2.124.
Stock Price History:
Over the past 52 weeks, GLYC has reached a high of $3.53, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -32.06%, while the 200-Day Moving Average is calculated to be -6.89%.
Shares Statistics:
According to the various share statistics, GLYC traded on average about 420.58K shares per day over the past 3-months and 767540 shares per day over the past 10 days. A total of 64.39M shares are outstanding, with a floating share count of 58.36M. Insiders hold about 9.46% of the company’s shares, while institutions hold 47.09% stake in the company. Shares short for GLYC as of 1711584000 were 1590887 with a Short Ratio of 3.78, compared to 1709164800 on 1559419. Therefore, it implies a Short% of Shares Outstanding of 1590887 and a Short% of Float of 3.56.
Earnings Estimates
The stock of GlycoMimetics Inc (GLYC) is currently drawing attention from GlycoMimetics, Inc. analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $841.25, with high estimates of $25.20 and low estimates of $840.40.
